Celleo’s first production Larkem® V40, with some of the development team.

Celleo is proud to announce the first customer delivery of a production Larkem® V40.  The system has been installed at the US facilities of a biopharma multinational, who manufacture groundbreaking CAR-T therapies for patients worldwide.

“It’s a privilege to support expanded manufacture of the world’s most important cell therapies,” announced CEO David Kneen.  “Today’s milestone reflects an extraordinary team effort, highlighting the experience and dedication of Celleo’s team, as well as the incredible contribution of our collaborators worldwide.”

Celleo’s Larkem® V40 is a closed, automated vial filling system for cell therapy production.  The system completes automated vial fills in minutes in a Grade C/D environment, delivering precise, homogeneous samples whilst being gentle on biology.  Applications include GMP manufacture of cell product and QC samples, cell banks, intermediates, viral vector and critical reagents.  Larkem drives robust, scalable cell therapy production by eliminating reliance on high-grade cleanrooms and replacing a cumbersome manual workflow with simple, intuitive automation.

“Extensive internal studies, backed by independent research at world-renowned institutes, have built strong confidence in the system’s capability across diverse cell and gene therapy applications,” noted Celleo Head of Biology Dr Nicholas Boyd.  “The research consistently demonstrates biological integrity across all key metrics, whilst delivering the operational and scalability benefits of rapid, closed processing.”

This milestone is an important step in Celleo’s mission – to drive population-level health outcomes by transforming cell therapy production.  The system is the first in a series of deliveries to leading customers across USA/Canada, Europe/UK and Asia-Pacific.

To learn more about how Larkem® V40 drives efficient, scalable production of cell and gene therapies, please contact us.